160 related articles for article (PubMed ID: 24998960)
1. Comparison of outcomes between women with de novo stage IV and relapsed breast cancer.
Kitagawa D; Horiguchi S; Yamashita T; Kuroi K; Shimizu K
J Nippon Med Sch; 2014; 81(3):139-47. PubMed ID: 24998960
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy.
Rossi V; Nolè F; Redana S; Adamoli L; Martinello R; Aurilio G; Verri E; Sapino A; Viale G; Aglietta M; Montemurro F
Breast; 2014 Feb; 23(1):44-9. PubMed ID: 24210572
[TBL] [Abstract][Full Text] [Related]
3. The Difference in Prognostic Outcomes Between
Yamamura J; Kamigaki S; Fujita J; Osato H; Komoike Y
In Vivo; 2018; 32(2):353-358. PubMed ID: 29475920
[TBL] [Abstract][Full Text] [Related]
4. Survival differences among women with de novo stage IV and relapsed breast cancer.
Dawood S; Broglio K; Ensor J; Hortobagyi GN; Giordano SH
Ann Oncol; 2010 Nov; 21(11):2169-2174. PubMed ID: 20427349
[TBL] [Abstract][Full Text] [Related]
5. [Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients].
Zhang P; Xu BH; Ma F; Li Q; Yuan P; Wang JY; Zhang P
Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):381-4. PubMed ID: 21875471
[TBL] [Abstract][Full Text] [Related]
6. Personalized Prognostic Prediction Models for Breast Cancer Recurrence and Survival Incorporating Multidimensional Data.
Wu X; Ye Y; Barcenas CH; Chow WH; Meng QH; Chavez-MacGregor M; Hildebrandt MA; Zhao H; Gu X; Deng Y; Wagar E; Esteva FJ; Tripathy D; Hortobagyi GN
J Natl Cancer Inst; 2017 Jul; 109(7):. PubMed ID: 28376179
[TBL] [Abstract][Full Text] [Related]
7. Hormone receptor status may impact the survival benefit of surgery in stage iv breast cancer: a population-based study.
Tan Y; Li X; Chen H; Hu Y; Jiang M; Fu J; Yuan Y; Ding K
Oncotarget; 2016 Oct; 7(43):70991-71000. PubMed ID: 27542240
[TBL] [Abstract][Full Text] [Related]
8. Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed.
den Brok WD; Speers CH; Gondara L; Baxter E; Tyldesley SK; Lohrisch CA
Breast Cancer Res Treat; 2017 Feb; 161(3):549-556. PubMed ID: 28000014
[TBL] [Abstract][Full Text] [Related]
9. Differential presentation and survival of de novo and recurrent metastatic breast cancer over time: 1990-2010.
Malmgren JA; Mayer M; Atwood MK; Kaplan HG
Breast Cancer Res Treat; 2018 Jan; 167(2):579-590. PubMed ID: 29039120
[TBL] [Abstract][Full Text] [Related]
10. A prognostic scoring model for survival after locoregional therapy in de novo stage IV breast cancer.
Kommalapati A; Tella SH; Goyal G; Ganti AK; Krishnamurthy J; Tandra PK
Breast Cancer Res Treat; 2018 Aug; 170(3):677-685. PubMed ID: 29721715
[TBL] [Abstract][Full Text] [Related]
11. Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study.
Lambertini M; Ferreira AR; Di Meglio A; Poggio F; Puglisi F; Sottotetti F; Montemurro F; Poletto E; Bernardo A; Risi E; Dellepiane C; Sini V; Minuti G; Grasso D; Fancelli S; Del Mastro L
Clin Breast Cancer; 2017 Dec; 17(8):601-610.e2. PubMed ID: 28479052
[TBL] [Abstract][Full Text] [Related]
12. De novo metastasis in breast cancer: occurrence and overall survival stratified by molecular subtype.
Press DJ; Miller ME; Liederbach E; Yao K; Huo D
Clin Exp Metastasis; 2017 Dec; 34(8):457-465. PubMed ID: 29288366
[TBL] [Abstract][Full Text] [Related]
13. [Clinical features and prognosis analysis of different breast cancer molecular subtypes].
Yang Q; Chen J; Li HJ; Yu M; Tian CX; Lü Q
Zhonghua Zhong Liu Za Zhi; 2011 Jan; 33(1):42-6. PubMed ID: 21575463
[TBL] [Abstract][Full Text] [Related]
14. [Clinicopathological characteristics and prognostic factors of breast cancer with estrogen- and progesterone-receptor negative and HER-2 overexpression].
Fan Y; Guan Y; Zhao WH; Li Q; Xu BH
Zhonghua Zhong Liu Za Zhi; 2008 Dec; 30(12):917-20. PubMed ID: 19173993
[TBL] [Abstract][Full Text] [Related]
15. Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer?
Lobbezoo DJ; van Kampen RJ; Voogd AC; Dercksen MW; van den Berkmortel F; Smilde TJ; van de Wouw AJ; Peters FP; van Riel JM; Peters NA; de Boer M; Peer PG; Tjan-Heijnen VC
Br J Cancer; 2015 Apr; 112(9):1445-51. PubMed ID: 25880008
[TBL] [Abstract][Full Text] [Related]
16. [Clinical characteristics and prognosis of different subtypes of breast cancer].
Yuan ZY; Wang SS; Zhu MQ; Zheng L; Luo WB; Zhou ZM; Guan ZZ
Zhonghua Zhong Liu Za Zhi; 2008 Jun; 30(6):456-61. PubMed ID: 19024523
[TBL] [Abstract][Full Text] [Related]
17. Treatment Outcomes and Prognostic Factors in Male Patients With Stage IV Breast Cancer: A Population-based Study.
Chen W; Huang Y; Lewis GD; Szeja SS; Hatch SS; Farach A; Miltenburg D; Butler EB; Chang JC; Teh BS
Clin Breast Cancer; 2018 Feb; 18(1):e97-e105. PubMed ID: 28888581
[TBL] [Abstract][Full Text] [Related]
18. The effect of distant metastases sites on survival in de novo stage-IV breast cancer: A SEER database analysis.
Wu SG; Li H; Tang LY; Sun JY; Zhang WW; Li FY; Chen YX; He ZY
Tumour Biol; 2017 Jun; 39(6):1010428317705082. PubMed ID: 28653887
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathologic factors associated with de novo metastatic breast cancer.
Shen T; Siegal GP; Wei S
Pathol Res Pract; 2016 Dec; 212(12):1167-1173. PubMed ID: 27692496
[TBL] [Abstract][Full Text] [Related]
20. Prognostic outcomes in advanced breast cancer: the metastasis-free interval is important.
Shen T; Gao C; Zhang K; Siegal GP; Wei S
Hum Pathol; 2017 Dec; 70():70-76. PubMed ID: 29031733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
